|
this system began paying a full commercial price during 2006.
In early 2007, Gen-Probe earned FDA approval to test
for WNV using the TIGRIS system, the first fully automated,
high-throughput molecular testing instrument for
blood screening. The TIGRIS system employs state-ofthe-
art process controls to minimize hands-on intervention
and the potential for human error. In addition, the
system can process 1,000 blood samples in about 14
hours. This level of productivity enables blood centers to
maximize the efficiency of testing and facilitates ”individual
donor testing,“ which increases screening sensitivity
and blood safety.
Another driver of Gen-Probe’s blood screening growth
in 2006 was international placements of the TIGRIS system,
and the resulting increase in sales of the PROCLEIX
ULTRIO assay. This assay, which simultaneously screens
donated blood for HIV-1, the hepatitis C virus (HCV), and
the hepatitis B virus (HBV), is approved for use on the
TIGRIS system outside the United States.
|
|
Andrew and Julie White, of New York, New York, understand the
importance of a safe blood supply. Their son, Nolan, was born at 27
weeks. During his three months in neonatal intensive care, he had
two life-saving blood transfusions. Today he is a precocious three year-
old who enjoys playing with his sister, Lauren.
|
